Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade [Seeking Alpha]
Benitec Biopharma (NASDAQ:BNTC) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response [Yahoo! Finance]